Cell MedX Corp.


Ticker Symbol: CMXC

Cell MedX Corp. (OTCQB: CMXC) is a development-stage bio-tech company focused on the commercialization and development of microcurrent therapeutic devices.

Company Overview

Cell MedX Corp. (OTCQB: CMXC) is a development-stage bio-tech company focused on the commercialization and development of microcurrent therapeutic devices that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.

Microcurrent therapy uses extremely low-level electrical currents to restore normal frequencies within cells, which can have a dramatic impact on health markers. In addition to increasing adenosine triphosphate (ATP) levels in cells, it enhances protein synthesis that can help with tissue repair. Increased blood flow and decreases in inflammation can lead to many possible benefits.

Investment Highlights

  • Proven Approach. Microcurrent technologies have been shown in clinical studies to increase adenosine triphosphate (ATP) levels in cells by up to 500% to accelerate healing and promote cellular-level wellness.
  • Proprietary Technology. Cell MedX Corp.’s eBalance Pro leverages proprietary software that reads the body and uses the information to emit electrical frequencies that are best-suited to help specific issues in different areas.

Download the Complete CMXC Company Analysis

Report

Download a free SECFilings Company Analysis on Cell MedX Corp. that covers:

  • Recent Developments - A review of recent developments and their impact on the company's bottom line.
  • Financial Analysis - A detailed review of the company's income statement, balance sheet, and cash flow statement.
  • Peer Comparison - A detailed list of industry peers and the company's relative valuation, growth rates, and much more.

Enter your e-mail below to receive the free analysis:

I also want to receive reports on similar opportunities in the space from time to time. We promise not to send spam.